Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

BACKGROUND: Lapatinib in combination with capecitabine is approved for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chew, Helen Kent, Schwartzberg, Lee, Badarinath, Suprith, Rubin, Peter, Shumaker, Grace, Daugherty, James, DeSilvio, Michelle, Mahoney, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447850/
https://www.ncbi.nlm.nih.gov/pubmed/26034656
http://dx.doi.org/10.1186/2193-1801-3-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447850/
https://www.ncbi.nlm.nih.gov/pubmed/26034656
http://dx.doi.org/10.1186/2193-1801-3-108

Ejemplares similares